UPDATE: Canaccord Genuity Starts Celgene (CELG) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
BMO Capital Positive on Celgene (CELG) REVLIMID Label Expansion
February 18, 2015 2:13 PM ESTBMO Capital analyst Jim Birchenough reiterated an Outperform rating and $163 price target on Celgene (NASDAQ: CELG) saying the REVLIMID label expansion in the U.S. should support continued growth.
Birchenough commented, "We are reiterating our Outperform rating on shares of the CELG... More
Celgene (CELG) Confirms No IPRs Filed; BofA/Merrill Lynch Sees Strong Revlimid Patents
February 18, 2015 6:50 AM ESTBofA/Merrill Lynch analyst Ying Huang reiterated a Buy rating and $136 price target on Celgene (NASDAQ: CELG) after the company confirmed that no Inter Partes Reviews (IPRs) have been filed to date on any of its products, including Revlimid and Pomalyst. Management also... More
